Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Microbiome-Based Hypothesis on Ivermectin’s Mechanism in COVID-19: Ivermectin Feeds Bifidobacteria to Boost Immunity

Hazan, S., Frontiers in Microbiology, doi:10.3389/fmicb.2022.952321
Jul 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now known with p < 0.00000000001 from 100 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19ivm.org
Hypothesis for an additional mechanism of action for ivermectin: inhibition of pro-inflammatory cytokines due to enhanced replication of Bifidobacterium.
This article was censored by the journal stating concerns "regarding the scientific validity", but providing no actual claim for any issue. The article only provides a hypothesis, while noting that supporting data is forthcoming.
Hazan et al., 11 Jul 2022, peer-reviewed, 1 author. Contact: drhazan@progenabiome.com.
This PaperIvermectinAll
Microbiome-Based Hypothesis on Ivermectin’s Mechanism in COVID-19: Ivermectin Feeds Bifidobacteria to Boost Immunity
Sabine Hazan
Frontiers in Microbiology, doi:10.3389/fmicb.2022.952321
Ivermectin is an anti-parasitic agent that has gained attention as a potential COVID-19 therapeutic. It is a compound of the type Avermectin, which is a fermented by-product of Streptomyces avermitilis. Bifidobacterium is a member of the same phylum as Streptomyces spp., suggesting it may have a symbiotic relation with Streptomyces. Decreased Bifidobacterium levels are observed in COVID-19 susceptibility states, including old age, autoimmune disorder, and obesity. We hypothesize that Ivermectin, as a by-product of Streptomyces fermentation, is capable of feeding Bifidobacterium, thereby possibly preventing against COVID-19 susceptibilities. Moreover, Bifidobacterium may be capable of boosting natural immunity, offering more direct COVID-19 protection. These data concord with our study, as well as others, that show Ivermectin protects against COVID-19.
AUTHOR CONTRIBUTIONS The author confirms being the sole contributor of this work and has approved it for publication. Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher. Copyright © 2022 Hazan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
References
Abbas, Muhammad, Ding, The effect of ivermectin on reducing viral symptoms in patients with mild COVID-19
Abd-Elsalam, Noor, Badawi, Khalaf, Esmail et al., Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: a randomized controlled study, J. Med. Virol, doi:10.1002/jmv.27122
Ahmed, Karim, Ross, Hossain, Clemens et al., A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int. J. Infect. Dis, doi:10.1016/j.ijid.2020.11.191
Ahsan, Rani, Siddiqui, D'souza, Memon et al., Clinical variants, characteristics, and outcomes among COVID-19 patients: a case series analysis at a tertiary care hospital in Karachi, Pakistan, doi:10.7759/cureus.14761
Alam, Murshed, Gomes, Masud, Saber et al., Ivermectin as pre-exposure prophylaxis for COVID-19 among healthcare providers in a selected tertiary hospital in Dhaka -an observational study, Eur. J. Med. Health Sci, doi:10.24018/ejmed.2020.2.6.599
Arboleya, Watkins, Stanton, Ross, Gut bifidobacteria populations in human health and aging, Front. Microbiol, doi:10.3389/fmicb.2016.01204
Aref, Bazeed, Hassan, Hassan, Rashad et al., Clinical, biochemical and molecular evaluations of ivermectin mucoadhesivenanosuspension nasal spray in reducing upper respiratory symptoms of mild COVID-19, Int. J. Nanomed, doi:10.2147/IJN.S313093
Ascencio-Montiel, Tomás-López, Álvarez-Medina, Gil-Velázquez, Vega-Vega et al., A multimodal strategy to reduce the risk of hospitalization/death in ambulatory patients with COVID-19, Arch. Med. Res, doi:10.1016/j.arcmed.2022.01.002
Babalola, Bode, Ajayi, Alakaloko, Akase et al., Ivermectin shows clinical benefits in mild to moderate COVID19: a randomized controlled double-blind, dose-response study in Lagos, QJM Int. J. Med, doi:10.1093/qjmed/hcab035
Barton, Nakanishi, Meth-Cohn, Comprehensive Natural Products Chemistry
Behera, Patro, Singh, Chandanshive, Ravikumar et al., Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: a matched case-control study, PLoS One, doi:10.1371/journal.pone.0247163
Beltran Gonzalez, González Gámez, Mendoza Enciso, Esparza Maldonado, Hernández Palacios et al., Efficacy and safety of ivermectin and hydroxychloroquine in patients with severe COVID-19: a randomized controlled trial, Infect. Dis. Rep, doi:10.3390/idr14020020
Bernstein, Cha, Second-Week Crash' is Time of Peril for Some Covid-19 Patients
Bozkurt, Bilen, Oral booster probiotic bifidobacteria in SARS-COV-2 patients, Int. J. Immunopathol. Pharmacol, doi:10.1177/20587384211059677
Bozkurt, Quigley, The probiotic Bifidobacterium in the management of Coronavirus: a theoretical basis, Int. J. Immunopathol. Pharmacol, doi:10.1177/2058738420961304
Buonfrate, Chesini, Martini, Roncaglioni, Ojeda Fernandez et al., High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dosefinding, proof-of-concept clinical trial, Int. J. Antimicrob. Agents, doi:10.1016/j.ijantimicag.2021.106516
Cadegiani, Goren, Wambier, Mccoy, Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients, New Microbes New Infect, doi:10.1016/j.nmni.2021.100915
Cervantes, Hong, The gut-lung axis in tuberculosis, Pathog. Dis, doi:10.1093/femspd/ftx097
Chaccour, Casellas, Blanco-Di Matteo, Pineda, Fernandez-Montero et al., The effect of early treatment with Hazan Ivermectin Feeds Bifidobacterium Fighting COVID-19
Chahla, Medina Ruiz, Ortega, Morales Rn, Barreiro et al., Intensive treatment with ivermectin and iota-carrageenan as pre-exposure prophylaxis for COVID-19 in health care workers from Tucuman, Argentina, Am. J. Ther, doi:10.1097/MJT.0000000000001433
Chowdhury, Shahbaz, Karim, Islam, Dan et al., A comparative study on ivermectin-doxycycline and hydroxychloroquine-azithromycin therapy on COVID-19 patients, Eurasian J. Med. Oncol, doi:10.14744/ejmo.2021.16263
Conte, Toraldo, Targeting the gut-lung microbiota axis by means of a high-fibre diet and probiotics may have anti-inflammatory effects in COVID-19 infection, Ther. Adv. Respir. Dis, doi:10.1177/1753466620937170
De, Vuyst, Moens, Selak, Rivière et al., Summer Meeting 2013: growth and physiology of bifidobacteria, J. Appl. Microbiol, doi:10.1111/JAM.12415
Dyakov, Mavletova, Chernyshova, Snegireva, Gavrilova et al., FN3 protein fragment containing two type III fibronectin domains from B. longum GT15 binds to human tumor necrosis factor alpha in vitro, Anaerobe, doi:10.1016/J.ANAEROBE.2020.102247
Elalfy, Besheer, El-Mesery, El-Gilany, Soliman et al., Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19, J. Med. Virol, doi:10.1002/jmv.26880
Faisal, Shah, Hussain, Potential use of azithromycin alone and in combination with ivermectin in fighting against the symptoms of COVID-19, Prof. Med. J, doi:10.29309/TPMJ/2021.28.05.5867
Ferreira, Beranger, Sampaio, Mansur Filho, Lima, Outcomes associated with Hydroxychloroquine and Ivermectin in hospitalized patients with COVID-19: a single-center experience, Rev. Assoc. Médica Bras, doi:10.1590/1806-9282.20210661
Gavriatopoulou, Ntanasis-Stathopoulos, Korompoki, Fotiou, Migkou et al., Emerging treatment strategies for COVID-19 infection, Clin. Exp. Med, doi:10.1007/s10238-020-00671-y
Gutiérrez-Castrellón, Gandara-Martí, Abreu, Abreu, Nieto-Rufino et al., Probiotic improves symptomatic and viral clearance in Covid19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial, Gut Microbes, doi:10.1080/19490976.2021.2018899
Hazan, Dave, Gunaratne, Dolai, Clancy et al., Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients, Future Microbiol, doi:10.2217/FMB-2022-0014
Hazan, Stollman, Bozkurt, Dave, Papoutsis et al., Lost microbes of COVID-19: Bifidobacterium,Faecalibacterium depletion and decreased microbiome diversity associated with SARS-CoV-2 infection severity, BMJ Open Gastroenterol, doi:10.1136/bmjgast-2022-000871
Heidary, Gharebaghi, Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen, J. Antibiot, doi:10.1038/s41429-020-0336-z
Hellwig, Maia, A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin, Int. J. Antimicrob. Agents, doi:10.1016/j.ijantimicag.2020.106248
Hughes, Harnisch, Alcon-Giner, Mitra, Wright et al., Bifidobacterium breve reduces apoptotic epithelial cell shedding in an exopolysaccharide and MyD88-dependent manner, Open Biol, doi:10.1098/RSOB.160155
Jabczyk, Nowak, Hudzik, Zubelewicz-Szkodzińska, Diet, probiotics and their impact on the gut microbiota during the COVID-19 pandemic, Nutrients, doi:10.3390/NU13093172
Joshi, Borah, Thakur, Sharma, Mayank et al., Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?, Hum. Vaccines Immunother, doi:10.1080/21645515.2021.1995283
Kerr, Cadegiani, Baldi, Lobo, Assagra et al., Ivermectin prophylaxis used for COVID-19: a citywide, prospective, observational study of 223,128 subjects using propensity score matching, Cureus, doi:10.7759/cureus.21272
Khaled, Probiotics, prebiotics, and COVID-19 infection: a review article, Saudi J. Biol. Sci, doi:10.1016/j.sjbs.2020.11.025
Khan, Khan, Debnath, Nath, Mahtab et al., Ivermectin treatment may improve the prognosis of patients with COVID-19, Arch. Bronconeumol, doi:10.1016/j.arbres.2020.08.007
Khodavirdipour, Asadimanesh, Masoumi, Impact of SARS-CoV-2 genetic blueprints on the oral manifestation of COVID-19: a case report, Glob. Med. Genet, doi:10.1055/s-0041-1735538
Khodavirdipour, Chamanrokh, Alikhani, Alikhani, Potential of Bacillus subtilis against SARS-CoV-2 -a sustainable drug development perspective, Front. Microbiol, doi:10.3389/fmicb.2022.718786
Khodavirdipour, Inclusion of cephalexin in COVID-19 treatment combinations may prevent lung involvement in mild infections: a case report with pharmacological genomics perspective, Glob. Med. Genet, doi:10.1055/s-0041-1726461
Khodavirdipour, Jabbari, Keramat, Alikhani, Concise update on genomics of COVID-19: approach to its latest mutations, escalated contagiousness, and vaccine resistance, Glob. Med. Genet, doi:10.1055/s-0041-1725143
Khodavirdipour, Keramat, Hamid Hashemi, Yousefalikhani, SARS-CoV-2; from vaccine development to drug discovery and prevention guidelines, AIMS Mol. Sci, doi:10.3934/molsci.2020013
Khodavirdipour, Piri, Jabbari, Khalaj-Kondori, Potential of CRISPR/Cas13 system in treatment and diagnosis of COVID-19, Glob. Med. Genet, doi:10.1055/s-0041-1723086
Kinobe, Owens, A systematic review of experimental evidence for antiviral effects of ivermectin and an in silico analysis of ivermectin's possible mode of action against SARS-CoV-2, Fundam. Clin. Pharmacol, doi:10.1111/fcp.12644
Kishoria, Mathur, Parmar, Kaur, Agarwal et al., Ivermectin as adjuvant to hydroxycholoroquine in patients resistant to standard treatment for Sars-Cov-2: results of an open-label randomized clinical study, Paripex Indian J. Res, doi:10.36106/paripex/4801859
Krolewiecki, Lifschitz, Moragas, Travacio, Valentini et al., Antiviral effect of high-dose ivermectin in adults with COVID-19: a proof-of-concept randomized trial, eClinicalMedicine, doi:10.1016/j.eclinm.2021.100959
Laing, Gillan, Devaney, Ivermectin -old drug, new tricks?, Trends Parasitol, doi:10.1016/j.pt.2017.02.004
Lazarenko, Babenko, Sichel, Pidgorskyi, Mokrozub et al., antagonistic action of lactobacilli and bifidobacteria in relation to Staphylococcus aureus and their influence on the immune response in cases of intravaginal Staphylococcosis in mice, Probiotics Antimicrob. Proteins, doi:10.1007/s12602-012-9093-z
Lehrer, Rheinstein, Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2, Vivo, doi:10.21873/invivo.12134
Lim, Hor, Tay, Mat, Jelani et al., Efficacy of ivermectin treatment on disease progression among adults with mild to moderate COVID-19 and comorbidities: the I-TECH randomized clinical trial, JAMA Intern. Med, doi:10.1001/jamainternmed.2022.0189
Lim, Shin, Antimicrobial and immunomodulatory effects of Bifidobacterium strains: a review, J. Microbiol. Biotechnol, doi:10.4014/JMB.2007.07046
Lima-Morales, Méndez-Hernández, Flores, Osorno-Romero, Sancho-Hernández et al., Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico, Int. J. Infect. Dis, doi:10.1016/j.ijid.2021.02.014
López-Medina, López, Hurtado, Dávalos, Ramirez et al., Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial, JAMA, doi:10.1001/jama.2021.3071
Markowiak, Śliżewska, Effects of probiotics, prebiotics, and synbiotics on human health, Nutrients, doi:10.3390/nu9091021
Mayer, Krolewiecki, Ferrero, Bocchio, Barbero et al., Safety and efficacy of a MEURI program for the use of high dose ivermectin in COVID-19 patients, Front. Public Health, doi:10.3389/fpubh.2022.813378
Mehta, Fajgenbaum, Is severe COVID-19 a cytokine storm syndrome: a hyperinflammatorydebate, Curr. Opin. Rheumatol, doi:10.1097/BOR.0000000000000822
Mohan, Tiwari, Suri, Mittal, Patel et al., Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): a single-centre randomized, placebo-controlled trial, J. Infect. Chemother, doi:10.1016/j.jiac.2021.08.021
Molyneux, Ward, Reflections on the nobel prize for medicine 2015 -the public health legacy and impact of Avermectin and Artemisinin, Trends Parasitol, doi:10.1016/j.pt.2015.10.008
Morgenstern, Redondo, Olavarria, Rondon, Roca et al., Ivermectin as a SARS-CoV-2 pre-exposure prophylaxis method in healthcare workers: a propensity score-matched retrospective cohort study, Cureus, doi:10.7759/cureus.17455
Mukarram, Ivermectin use associated with reduced duration of Covid-19 febrile illness in a community setting, Int. J. Clin. Stud. Med. Case Rep, doi:10.46998/IJCMCR.2021.13.000320
Mustafa, Kow, Salman, Kanwal, Riaz et al., Pattern of medication utilization in hospitalized patients with COVID-19 in three District Headquarters Hospitals in the Punjab province of Pakistan, Explor. Res. Clin. Soc. Pharm, doi:10.1016/j.rcsop.2021.100101
Okumuş, Demirtürk, Çetinkaya, Güner, Avcı et al., Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients, BMC Infect. Dis, doi:10.1186/s12879-021-06104-9
Ozer, Goksu, Conception, Ulker, Balderas et al., Effectiveness and safety of Ivermectin in COVID-19 patients: a prospective study at a safety-net hospital, J. Med. Virol, doi:10.1002/jmv.27469
Podder, Chowdhury, Sina, Haque, Outcome of ivermectin treated mild to moderate COVID-19 cases: a singlecentre, open-label, randomised controlled study, IMC J. Med. Sci, doi:10.3329/imcjms.v14i2.52826
Rajter, Sherman, Fatteh, Vogel, Sacks et al., Use of ivermectin is associated with lower mortality in hospitalized patients with Coronavirus disease, Chest, doi:10.1016/j.chest.2020.10.009
Ravikirti, Pattadar, Raj, Agarwal, Biswas, Evaluation of ivermectin as a potential treatment for mild to moderate COVID-19: a double-blind randomized placebo controlled trial in Eastern India, J. Pharm. Pharm. Sci, doi:10.18433/jpps32105
Reaz, Rahman, Iftikher, Ahmed, Kabir et al., Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial, J. Int. Med. Res, doi:10.5061/DRYAD.QJQ2BVQF6
Reinold, Farahpour, Fehring, Dolff, Konik et al., A pro-inflammatory gut microbiome characterizes SARS-CoV-2 infected patients and a reduction in the connectivity of an anti-inflammatory bacterial network associates with severe COVID-19, Front. Cell. Infect. Microbiol, doi:10.3389/fcimb.2021.747816
Reis, Silva, Silva, Thabane, Milagres et al., Effect of early treatment with ivermectin among patients with Covid-19, N. Engl. J. Med, doi:10.1056/NEJMoa2115869
Rezk, Elsayedsileem, Gad, Khalil, miRNA-223-3p, miRNA-2909 and cytokines expression in COVID-19 patients treated with ivermectin, Zagazig Univ. Med. J, doi:10.21608/zumj.2021.92746.2329
Rivière, Selak, Lantin, Leroy, Vuyst, Bifidobacteria and butyrate-producing colon bacteria: importance and strategies for their stimulation in the human gut, Front. Microbiol, doi:10.3389/fmicb.2016.00979
Rizzo, Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action, Naunyn. Schmiedebergs Arch. Pharmacol, doi:10.1007/s00210-020-01902-5
Ruiz, Delgado, Ruas-Madiedo, Sánchez, Margolles, Bifidobacteria and their molecular communication with the immune system, Front. Microbiol, doi:10.3389/fmicb.2017.02345
Saha, Raihan, The binding mechanism of ivermectin and levosalbutamol with spike protein of SARS-CoV-2, Struct. Chem, doi:10.1007/s11224-021-01776-0
Seet, Quek, Ooi, Sengupta, Lakshminarasappa et al., Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: an open-label randomized trial, Int. J. Infect. Dis, doi:10.1016/j.ijid.2021.04.035
Seipke, Kaltenpoth, Hutchings, Shahbaznejad, Davoudi et al., Effects of ivermectin in patients with COVID-19: a multicenter, double-blind, randomized, controlled clinical trial, FEMS Microbiol. Rev, doi:10.1016/j.clinthera.2021.04.007
Sharma, Ahmad Farouk, Lal, COVID-19: a review on the novel coronavirus disease evolution, transmission, detection, control and prevention, Viruses, doi:10.3390/v13020202
Shimizu, Hirata, Kabata, Tokuhira, Koide et al., Ivermectin administration is associated with lower gastrointestinal complications and greater ventilator-free days in ventilated patients with COVID-19: a propensity score analysis, J. Infect. Chemother, doi:10.1016/j.jiac.2021.12.024
Shoumann, Hegazy, Nafae, Ragab, Samra et al., Use of ivermectin as a potential chemoprophylaxis for COVID-19 in egypt: a randomised clinical trial, J. Clin. Diagn. Res, doi:10.7860/JCDR/2021/46795.14529
Tao, Zhang, Wang, Guo, Zeng et al., Analysis of the intestinal microbiota in COVID-19 patients and its correlation with the inflammatory factor IL-18, Med. Microecol, doi:10.1016/j.medmic.2020.100023
Xu, Cai, Shen, Ni, Chen et al., Management of corona virus disease-19 (COVID-19): the Zhejiang experience
Xuexuebao, Xue Ban, None, Zhejiang Univ. Med. Sci
Yeoh, Zuo, Lui, Zhang, Liu et al., Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19, Gut, doi:10.1136/gutjnl-2020-323020
Zayet, Gendrin, Klopfenstein, Natural history of COVID-19: back to basics, New Microbes New Infect, doi:10.1016/j.nmni.2020.100815
Zhang, Albermann, Fu, Thorson, The in vitro characterization of the iterative avermectin glycosyltransferase AveBI reveals reaction reversibility and sugar nucleotide flexibility, J. Am. Chem. Soc, doi:10.1021/JA065950K
Zubair, Chaudhry, Zubairi, Shahzad, Zahid et al., The effect of ivermectin on non-severe and severe COVID-19 disease and gender-based difference of its effectiveness, Monaldi Arch. Chest Dis, doi:10.4081/monaldi.2022.2062
Zuo, Wu, Wen, Lan, Gut microbiome alterations in COVID-19, Genomics Proteomics Bioinformatics
Ômura, Crump, Ivermectin: panacea for resource-poor communities?, Trends Parasitol, doi:10.1016/j.pt.2014.07.005
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit